BioMarin Q3 2026 slides: first $1B quarter, guidance cut on timing
BioMarin (BMRN) reported Q3 2026 revenue of $1.025B, up 32% YoY, and EPS of $0.23, up 92% YoY. Despite this, it cut full-year guidance due to order delays, with revenue now expected at $3.8B-$3.9B and EPS at $2.80-$3.10. The stock fell 5.12% in after-hours trading.
How this was made
The 30-second read
Why it matters
Guidance reduction and order deferral caused a 5.12% after‑hours decline, suggesting near‑term downside risk.
Market read
First‑report earnings and guidance cut provide fresh material for traders; price reaction already evident.
What to watch
Synergies from the Amicus acquisition and pipeline expansions may offset near‑term revenue deferral.
Background
BioMarin reported its first quarter exceeding $1B in revenue, but cut full‑year guidance due to a timing issue with a single international customer.
Ticker impact
Q3 2026 results showed $1.025B revenue and cut full-year guidance, shares fell 5.12% after-hours.
likely pressure as the market prices in the lower revenue and EPS outlook
The company reduced 2026 revenue guidance to $3.8-$3.9B and EPS to $2.80-$3.10 after reporting $1.025B revenue, causing a 5.12% after‑hours decline.
Market effects
Biotech sector may see broader sell‑off as guidance cuts raise concerns about order timing risk.
U.S. biotech stocks could face short‑term weakness in pre‑market trading.
Limited to investors with exposure to rare‑disease therapeutics; no immediate global macro effect.
Counterpoint
The $1B revenue milestone could signal long‑term growth potential despite short‑term guidance cut.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech reporting Q3 2026 results.
